Understanding antiretroviral (ARV) pharmacology in the genital tract (GT) is critically important, as these therapies have the potential to decrease sexual transmission of HIV by reducing HIV RNA and rendering the infected person less infectious, or by pre- or post-exposure prophylaxis. Low concentrations of ARVs in the GT may render pre-and post-exposure prophylaxis regimens ineffective, and may result in the emergence of drug resistant HIV mutations that could impact HIV transmission to others, and result in antiretroviral failure in an individual patient. This proposal examines the pharmacokinetic/pharmacodynamic relationships of ARVs and virologic response in the genital tract.
Three Specific Aims are proposed.
In Specific Aim 1, the complete pharmacokinetics of 14 ARVs in directly-aspirated female GT secretions will be determined.
In Specific Aim 2, we propose to evaluate GT intracellular pharmacology by measuring nucleoside analogue mono, di, and triphosphate concentrations in male and female mononuclear cells derived from blood and GT secretions.
In Specific Aim 3, HIV compartmentalization in the female genital tract will be assessed by developing pharmacokinetic/pharmacodynamic and statistical models to evaluate the relationship between virologic response rates in the female GT, and blood plasma HIV RNA, ARV exposure in blood plasma, and ARV exposure in the GT. The research projects described in this application form the core of a 5-year career development plan for Dr. Angela Kashuba, an assistant professor in the School of Pharmacy. Her mentor, Dr. Myron Cohen is an established HIV investigator, is Chief of the Division of Infectious Diseases (ID) in the School of Medicine, and Director of the UNC Center for Infectious Diseases (CFID). Her co-mentor Dr. Kim Brouwer has significant experience in the design, conduct, and analysis of clinical studies focusing on drug disposition and action. Her co-mentor Dr. Richard Tidwell has conducted extensive research in the design, testing and development of new agents for treatment of AIDS-associated opportunistic infections over the last 10 years. They propose a combined didactic and clinical research experience, utilizing the resources of the UNC CFAR and CFID, and the UNC General Clinical Research Center to foster Dr. Kashuba's research skills in evaluating ARV pharmacokinetic/pharmacodynamic relationships in the GT. They have assembled a carefully selected group of collaborators and advisors to assist in these research projects and Dr. Kashuba's career development. The long-term objectives of this project are to: 1) impact HIV transmission by advancing the science of ARV pharmacology and virology in the male and female GT in order to optimally chose effective combinations of antiretroviral therapies, and 2) to develop the applicant's skills in statistical, epidemiological, pharmacokinetic/dynamic modeling, and analytical methods in pharmacology pursuant to a career in clinical pharmacology research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
5K23AI054980-04
Application #
7028282
Study Section
Acquired Immunodeficiency Syndrome Research Review Committee (AIDS)
Program Officer
Zhang, Hao
Project Start
2003-04-01
Project End
2008-02-29
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
4
Fiscal Year
2006
Total Cost
$126,630
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Patterson, Kristine B; Dumond, Julie B; Prince, Heather A et al. (2013) Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines. J Acquir Immune Defic Syndr 63:51-8
Brown, Kevin C; Patterson, Kristine B; Jennings, Steven H et al. (2012) Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men. J Acquir Immune Defic Syndr 61:138-44
Dumond, Julie B; Nicol, Melanie R; Kendrick, Racheal N et al. (2012) Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Clin Pharmacokinet 51:809-22
Brown, Kevin C; Patterson, Kristine B; Malone, Stephanie A et al. (2011) Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis 203:1484-90
Choi, S O; Rezk, N; Kim, J S et al. (2010) Development of an LC-MS method for measuring TNF in human vaginal tissue. J Chromatogr Sci 48:219-23
Jones, Amanda E; Brown, Kevin C; Werner, Rebecca E et al. (2010) Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol 66:475-85
Dumond, J B; Vourvahis, M; Rezk, N L et al. (2010) A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 87:735-42
McRae, MaryPeace; Rezk, Naser L; Bridges, Arlene S et al. (2010) Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity. Pharmacotherapy 30:17-24
Dumond, Julie B; Patterson, Kristine B; Pecha, Allison L et al. (2009) Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 51:546-53
Yeh, Rosa F; Rezk, Naser L; Kashuba, Angela D M et al. (2009) Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother 53:2367-74

Showing the most recent 10 out of 33 publications